Merck Serono
| Merck Serono | |
|---|---|
| EMD Serono | |
| Type | Stock corporation |
| Founded | 1668 |
| Location | Darmstadt, Germany (Headquarters)
|
| Key people | |
| Industry | Pharmaceutical
|
| Key Products | Bavencio
|
| Revenue | USD ~5 billion (projected) |
| Website | www www |
Merck Serono (EMD Serono in the
Merck focused on biopharmaceuticals.[1]
In September 2006,
Geneva, Switzerland
to Darmstadt.
Drugs they market include
Raptiva
was withdrawn in 2007.
In the U.S. and Canada, Merck Serono is known as EMD Serono, as the former Merck subsidiary Merck & Co. holds the rights to the name Merck in those countries.
Collaborative research
In addition to internal research and development activities Merck Serono with the help of Toledana, is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of
EFPIA and the European Commission.[4]
Notes and references
- ^ Background Info, www.merckserono.com
- PMID 18449490.
- ^ "InnoMed PredTox Member Organizations". Archived from the original on 26 September 2008. Retrieved 2008-08-25.
- ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 15 October 2009. Retrieved 25 August 2008.
See also
- List of pharmaceutical companies
- Pharmaceutical industry in Switzerland
- Campus Biotech
- Sutro Biopharma
External links
Wikimedia Commons has media related to Merck Serono.
| International | |
|---|---|
| National | |
| Other | |
